115 related articles for article (PubMed ID: 6206435)
1. Tritiated-6-beta-fluoro-6-desoxy-oxymorphone: a highly selective ligand for the opiate mu receptor whose binding is characterized by low nonspecific binding.
Rothman RB; Danks JA; Jacobson AE; Burke TR; Rice KC; Pert CB
Neuropeptides; 1984 Jun; 4(4):311-7. PubMed ID: 6206435
[TBL] [Abstract][Full Text] [Related]
2. Tritiated-6-beta-fluoro-6-desoxy-oxymorphone ([3H]FOXY): a new ligand and photoaffinity probe for the mu opioid receptors.
Rothman RB; Bykov V; Rice KC; Jacobson AE; Kooper GN; Bowen WD
Neuropeptides; 1988 Jan; 11(1):1-6. PubMed ID: 2835700
[TBL] [Abstract][Full Text] [Related]
3. Preparation of rat brain membranes greatly enriched with either type-I-delta or type-II-delta opiate binding sites using site directed alkylating agents: evidence for a two-site allosteric model.
Rothman RB; Bowen WD; Bykov V; Schumacher UK; Pert CB; Jacobson AE; Burke TR; Rice KC
Neuropeptides; 1984 May; 4(3):201-15. PubMed ID: 6087189
[TBL] [Abstract][Full Text] [Related]
4. Antagonist-induced opioid receptor up-regulation. II. Regionally specific modulation of mu, delta and kappa binding sites in rat brain revealed by quantitative autoradiography.
Morris BJ; Millan MJ; Herz A
J Pharmacol Exp Ther; 1988 Nov; 247(2):729-36. PubMed ID: 2846828
[TBL] [Abstract][Full Text] [Related]
5. A quantitative study of [3H]D-Ala2-D-Leu5-enkephalin binding to rat brain membranes. Evidence that oxymorphone is a noncompetitive inhibitor of the lower affinity delta-binding site.
Rothman RB; Bowen WD; Herkenham M; Jacobson AE; Rice KC; Pert CB
Mol Pharmacol; 1985 Mar; 27(3):399-409. PubMed ID: 2579319
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological and anatomical evidence of selective mu, delta, and kappa opioid receptor binding in rat brain.
Mansour A; Lewis ME; Khachaturian H; Akil H; Watson SJ
Brain Res; 1986 Dec; 399(1):69-79. PubMed ID: 3026574
[TBL] [Abstract][Full Text] [Related]
7. Multiple opiate binding sites in the central nervous system of the rabbit. Large predominance of a mu subtype in the cerebellum and characterization of a kappa subtype in the thalamus.
Meunier JC; Kouakou Y; Puget A; Moisand C
Mol Pharmacol; 1983 Jul; 24(1):23-9. PubMed ID: 6306437
[TBL] [Abstract][Full Text] [Related]
8. Autoradiographic localization in rat brain of kappa opiate binding sites labelled by [3H]bremazocine.
Morris BJ; Herz A
Neuroscience; 1986 Nov; 19(3):839-46. PubMed ID: 3025770
[TBL] [Abstract][Full Text] [Related]
9. Opiate binding in the rat spinal cord: evidence for mu and delta sites.
Traynor JR; Rance MJ
Neuropeptides; 1984 Dec; 5(1-3):81-4. PubMed ID: 6099519
[TBL] [Abstract][Full Text] [Related]
10. Morphine tolerance increases mu-noncompetitive delta binding sites.
Rothman RB; Danks JA; Jacobson AE; Burke TR; Rice KC; Tortella FC; Holaday JW
Eur J Pharmacol; 1986 May; 124(1-2):113-9. PubMed ID: 3013657
[TBL] [Abstract][Full Text] [Related]
11. Pretreatment of rats with the irreversible mu-receptor antagonist, beta-FNA, fails to prevent naltrexone-induced upregulation of mu-opioid receptors.
Rothman RB; Long JB; Bykov V; Jacobson AE; Rice KC; Holaday JW
Neuropharmacology; 1990 Sep; 29(9):805-10. PubMed ID: 1963479
[TBL] [Abstract][Full Text] [Related]
12. Ionic conditions differentially affect 3H-DADL binding to type-I and type-II opiate delta receptors in vitro.
Rothman RB; Danks JA; Pert CB; Jacobson AE; Burke TR; Rice KC
Neuropeptides; 1984 May; 4(3):261-8. PubMed ID: 6087192
[TBL] [Abstract][Full Text] [Related]
13. Autoradiographic evidence for two classes of mu opioid binding sites in rat brain using [125I]FK33824.
Rothman RB; Jacobson AE; Rice KC; Herkenham M
Peptides; 1987; 8(6):1015-21. PubMed ID: 2831515
[TBL] [Abstract][Full Text] [Related]
14. Differential coupling of mu-competitive and mu-noncompetitive delta opiate receptors to guanine nucleotide binding proteins in rat brain membranes.
Bowen WD; Rodrigues PA; Wanzor TE; Jacobson AE; Rice KC
Biochem Pharmacol; 1988 Feb; 37(3):467-72. PubMed ID: 2827687
[TBL] [Abstract][Full Text] [Related]
15. Preparation of [3H]-oxymorphazone and its binding to rat brain membranes.
Borsodi A; Varga E; Toth G; Hosztafi S
NIDA Res Monogr; 1986; 75():220-3. PubMed ID: 2448626
[TBL] [Abstract][Full Text] [Related]
16. Sulfonic acid enkephalin: binding specificity to rat brain opiate receptors.
Martin JL; Coletti-Previero MA; Roques BP; Descomps B
Neuropeptides; 1985 Jul; 6(4):293-302. PubMed ID: 2995863
[TBL] [Abstract][Full Text] [Related]
17. Preparation of rat brain membranes highly enriched with opiate kappa binding sites using site-directed acylating agents: optimization of assay conditions.
Rothman RB; Bykov V; Danks JA; Jacobson AE; Burke TR; Rice KC; Herkenham M
Neuropeptides; 1985 Dec; 6(6):503-16. PubMed ID: 3001575
[TBL] [Abstract][Full Text] [Related]
18. Oxymorphone-naltrexonazine, a mixed opiate agonist-antagonist.
Galetta S; Hahn EF; Nishimura S; Pasternak GW
Life Sci; 1987 Aug; 41(6):783-7. PubMed ID: 2441221
[TBL] [Abstract][Full Text] [Related]
19. The occurrence and receptor specificity of endogenous opioid peptides within the pancreas and liver of the rat. Comparison with brain.
Khawaja XZ; Green IC; Thorpe JR; Titheradge MA
Biochem J; 1990 Apr; 267(1):233-40. PubMed ID: 1970240
[TBL] [Abstract][Full Text] [Related]
20. Autoradiographic localization of opiate kappa-receptors in the guinea-pig brain.
Foote RW; Maurer R
Eur J Pharmacol; 1982 Nov; 85(1):99-103. PubMed ID: 6295776
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
